Company intelligence / Profile preview

Guanhao Biotech

Guangzhou, Guangdong, China

Ownership: Private
Employees: ~530
Development stage: Commercial

Overview

Guanhao Biotech markets several commercial regenerative medical devices and wound care products in China. Its small molecule drug Benvitimod has reached Phase 3 trials for dermatological indications. The company also has an mRNA-based COVID‑19 vaccine in discovery.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculemRNA vaccineProphylactic vaccineMedical device (biological patches, wound dressings, etc.)
Industry: Biotech

Beyond the preview

Go deeper on Guanhao Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guanhao Biotech.

Explore the full profile